Effect of recombinant mouse interferon-beta on acute and latent herpes simplex infection in mice.
The antiviral effect of recombinant mouse interferon-beta (rMuIFN-beta) on herpes simplex virus type 1 (HSV-1) in experimentally infected mice was examined at several stages of infection as a model for the treatment of human HSV infection. Recombinant MuIFN-beta protected mice from lethal intraperitoneal challenge with virulent HSV-1 strains. The in vitro reactivation of HSV from latently infected trigeminal ganglia was also suppressed by treatment with rMuIFN-beta. Thus, rMuIFN-beta was effective against HSV-1 during acute infection and during in vitro reactivation of latent HSV. However, rMuIFN-beta was not effective in preventing the establishment of latent infection, or in eliminating a previously established latent infection.
Yamada
M
M
Department of Virology, Okayama University Medical School, Japan.
Arao
Y
Y
Hatano
A
A
Uno
F
F
Nii
S
S
D000208:Acute Disease; D000818:Animals; D002460:Cell Line; D002908:Chronic Disease; D006561:Herpes Simplex / Q000517:prevention & control / Q000628:therapy*; D007370:Interferon Type I / Q000494:pharmacology*; D051379:Mice; D011994:Recombinant Proteins / Q000494:pharmacology; D013045:Species Specificity; D014709:Vero Cells; D014762:Viral Interference; D014779:Virus Replication / Q000187:drug effects
D007370:Interferon Type I; D011994:Recombinant Proteins